In summary, we therefore extend our previous data describing the promotion of drug resistance by a platinum chemotherapy-induced increase in FGF1 expression, and highlight that pharmacological inhibition of FGF signalling can re-sensitise both immortalised drug-resistant cells and primary cell lines from drug-resistant ovarian cancer patients. The gene discussed is FGF1; the disease is ovarian cancer.